Exploring the altered dynamics of mammalian central carbon metabolic pathway in cancer cells: A classical control theoretic approach

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Paul, Debjyoti ^a   Dasgupta, Abhijit ^a   De, Rajat K ^a  

^a INDIAN STATISTICAL INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOLYTIC ENZYME; PENTOSE PHOSPHATE; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG; CARBON;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL METABOLISM; CENTRAL CARBON METABOLIC PATHWAY; CLASSICAL CONTROL THEORY; CONTROLLED STUDY; ENZYME MECHANISM; ERYTHROCYTE; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MICHAELIS MENTEN KINETICS; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; THEORY; ANIMAL; BIOLOGICAL MODEL; METABOLISM; NEOPLASM;

ANIMALS; CARBON; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84947775955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137728     Document Type: Article

References (35)

1. Resendis-Antonio O, Checa A, Encarnación S. Modeling core metabolism in cancer cells: Surveying the topology underlying the Warburg effect. PLoS One. 2010; 5(8): E12383. doi: 10.1371/Journal.pone. 0012383 PMID: 20811631
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009; 324(5930): 1029-1033. doi: 10.1126/science. 1160809 PMID: 19460998
3. Kauffman KJ, Prakash P, Edwards JS. Advances in flux balance analysis. Current Opinion in Biotechnology. 2003; 14(5): 491-496. doi: 10.1016/j.copbio.2003.08.001 PMID: 14580578
4. De RK, Das M, Mukhopadhyay S. Incorporation of enzyme concentrations into FBA and identification of optimal metabolic pathways. BMC Systems Biology. 2008; 2(1): 65. doi: 10.1186/1752-0509-2-65 PMID: 18634554
5. De RK, Tomar N. Modeling the optimal carbon metabolic pathways under feedback inhibition using flux balance analysis. Journal of Bioinformatics and Computational Biology. 2012; 10(06). doi: 10.1142/S0219720012500199 PMID: 22913632
6. Acerenza L, Sauro HM, Kacser H. Control analysis of time-dependent metabolic systems. Journal of Theoretical Biology. 1989; 137(4): 423-444. doi: 10.1016/S0022-5193(89)80038-4 PMID: 2626059
7. Cascante M, Boros LG, Comin-Anduix B, de Atauri P, Centelles JJ, Lee PWN. Metabolic control analysis in drug discovery and disease. Nature Biotechnology. 2002; 20(3): 243-249. doi: 10.1038/nbt0302-243 PMID: 11875424
8. Kholodenko BN, Demin OV, Westerhoff HV. Control analysis of periodic phenomena in biological systems. The Journal of Physical Chemistry B. 1997; 101(11): 2070-2081. doi: 10.1021/jp962336u
9. Wildermuth MC. Metabolic control analysis: Biological applications and insights. Genome Biology. 2000; 1(6): 1031-1. doi: 10.1186/gb-2000-1-6-reviews1031
10. Rao, CV, Sauro, HM, Arkin, AP. Putting the control in metabolic control analysis,. In: 7th International Symposium on Dynamics and Control of Process Systems, DYCOPS. vol. 7; 2004.
11. Panja S, Patra S, Mukherjee A, Basu M, Sengupta S, Dutta PK. A closed-loop control scheme for steering steady states of glycolysis and glycogenolysis pathway. IEEE/ACM Transactions on Computational Biology and Bioinformatics (TCBB). 2013; 10(4): 858-868. doi: 10.1109/TCBB.2013.82
12. Nelson DL, Lehninger AL, Cox MM. Lehninger Principles of Biochemistry. Macmillan; 2008.
13. Morris KA. Introduction to Feedback Control. Academic Press, Inc.; 2000.
14. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell. 2008; 13 (6): 472-482. doi: 10.1016/j.ccr.2008.05.005 PMID: 18538731
15. Marín-Hernández A, Gallardo-Pérez JC, Rodríguez-Enríquez S, Encalada R, Moreno-Sánchez R, Saavedra E. Modeling cancer glycolysis. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2011; 1807 (6): 755-767. doi: 10.1016/j.bbabio.2010.11.006
16. Chang R. Physical Chemistry for the Biosciences. University Science Books; 2005.
17. Gerdtzen ZP, Daoutidis P, Hu WS. Non-linear reduction for kinetic models of metabolic reaction networks. Metabolic Engineering. 2004; 6(2): 140-154. doi: 10.1016/j.ymben.2003.11.003 PMID: 15113567
18. Famili I, Palsson BO. The convex basis of the left null space of the stoichiometric matrix leads to the definition of metabolically meaningful pools. Biophysical Journal. 2003; 85(1): 16-26. doi: 10.1016/S0006-3495(03)74450-6 PMID: 12829460
19. Qian H, Beard DA, Liang Sd. Stoichiometric network theory for nonequilibrium biochemical systems. European Journal of Biochemistry. 2003; 270(3): 415-421. doi: 10.1046/j.1432-1033.2003.03357.x PMID: 12542691
20. Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N, et al. COPASIa complex pathway simulator. Bioinformatics. 2006; 22(24): 3067-3074. doi: 10.1093/bioinformatics/btl485 PMID: 17032683
21. Chassagnole C, Noisommit-Rizzi N, Schmid JW, Mauch K, Reuss M. Dynamic modeling of the central carbon metabolism of Escherichia coli. Biotechnology and Bioengineering. 2002; 79(1): 53-73. doi: 10.1002/bit.10288 PMID: 17590932
22. Shlomi T, Cabili MN, Herrgård MJ, Palsson BO, Ruppin E. Network-based prediction of human tissuespecific metabolism. Nature Biotechnology. 2008; 26(9): 1003-1010. doi: 10.1038/nbt.1487 PMID: 18711341
23. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 2010; 329 (5998): 1492-1499. doi: 10.1126/science.1188015 PMID: 20847263
24. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452 (7184): 230-233. doi: 10.1038/nature06734 PMID: 18337823
25. Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proceedings of the National Academy of Sciences, USA. 2010; 107(5): 1894-1899. doi: 10.1073/pnas. 0914845107
26. Huang L, Yu Z, Zhang T, Zhao X, Huang G. HSP40 interacts with pyruvate kinase M2 and regulates glycolysis and cell proliferation in tumor cells. PLoS One. 2014; 9(3): E92949. doi: 10.1371/Journal. pone.0092949 PMID: 24658033
27. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008; 452(7184): 181-186. doi: 10.1038/nature06667 PMID: 18337815
28. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature Chemical Biology. 2012; 8(10): 839-847. doi: 10.1038/nchembio.1060 PMID: 22922757
29. Iqbal MA, Gupta V, Gopinath P, Mazurek S, Bamezai RN. Pyruvate kinase M2 and cancer: An updated assessment. Federation of European Biochemical Societies Letters. 2014; . doi: 10.1016/j.febslet.2014. 04.011 PMID: 24747424
30. Mazurek S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. The International Journal of Biochemistry & Cell Biology. 2011; 43(7): 969-980. doi: 10.1016/j.biocel. 2010.02.005
31. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science Signaling. 2009; 2(97): Ra73. doi: 10.1126/scisignal.2000431 PMID: 19920251
32. Wong N, De Melo J, Tang D. PKM2, a central point of regulation in cancer metabolism. International Journal of Cell Biology. 2013; 2013. doi: 10.1155/2013/242513 PMID: 23476652
33. Vander Heiden MG. Targeting cancer metabolism: A therapeutic window opens. Nature Reviews Drug Discovery. 2011; 10(9): 671-684. doi: 10.1038/nrd3504 PMID: 21878982
34. Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends in Endocrinology & Metabolism. 2012; 23(11): 560-566. doi: 10.1016/j.tem.2012.06.010
35. Mazurek S. Pyruvate kinase M2: A key enzyme of the tumor metabolome and its medical relevance. Biomed Res. 2012; 23: 133-141.